The design and synthesis of a novel series of oxazole-, thiazole-, and imidazole-based inhibitors of I kappa B kinase (IKK) are reported. Biological activity was improved compared to the pyrazolopurine lead, and the expedient synthesis of the new tricyclic systems allowed for efficient exploration of structure-activity relationships. This, combined with an iterative rat cassette dosing strategy, was used to identify compounds with improved pharmacokinetic (PK) profiles to advance for in vivo evaluation.
作者:James Kempson、Steven H. Spergel、Junqing Guo、Claude Quesnelle、Patrice Gill、Dominique Belanger、Alaric J. Dyckman、Tianle Li、Scott H. Watterson、Charles M. Langevine、Jagabandhu Das、Robert V. Moquin、Joseph A. Furch、Anne Marinier、Marco Dodier、Alain Martel、David Nirschl、Katy Van Kirk、James R. Burke、Mark A. Pattoli、Kathleen Gillooly、Kim W. McIntyre、Laishun Chen、Zheng Yang、Punit H. Marathe、David Wang-Iverson、John H. Dodd、Murray McKinnon、Joel C. Barrish、William J. Pitts
DOI:10.1021/jm8015816
日期:2009.4.9
The design and synthesis of a novel series of oxazole-, thiazole-, and imidazole-based inhibitors of I kappa B kinase (IKK) are reported. Biological activity was improved compared to the pyrazolopurine lead, and the expedient synthesis of the new tricyclic systems allowed for efficient exploration of structure-activity relationships. This, combined with an iterative rat cassette dosing strategy, was used to identify compounds with improved pharmacokinetic (PK) profiles to advance for in vivo evaluation.